Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

DNA, DNA double-helix

News and Trends 20 Dec 2022

Ribbon Biolabs milestone to lead to 2023 market entry

DNA synthesis company Ribbon Biolabs has announced the successful implementation of its InfiniSynth platform for the automated assembly of sequence-agnostic and long DNA. The company achieved the milestone in collaboration with HighRes Biosolutions, a laboratory automation technology company. The InfiniSynth platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

Pancreatic Cancer

News and Trends 20 Dec 2022

iOnctura raises €17.5M for pancreatic cancer therapy

iOnctura BV, a clinical-stage biotech developing novel cancer therapies, has been granted €17.5 million ($18.6 million) funding from the European Investment Council’s (EIC) accelerator program to develop IOA-289 for pancreatic cancer. The EIC’s funding consists of a grant of €2.5 million ($2.7 million), and €15 million ($16 million) of equity investment. Earlier this month, iOnctura […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

fungi fungal infections Scopulariopsis brevicaulis

News and Trends 20 Dec 2022

F2G looks for FDA new drug application approval for invasive fungal infections treatment

F2G Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its new drug application (NDA) for olorofim for the treatment of invasive fungal infections in patients who have limited or no treatment options. F2G has requested approval of the NDA under the Limited Population Pathway for Antibacterial and Antifungal […]

December 20, 2022 - 3 minutesmins - By Jim Cornall

green bioactives Anastasiia Slynko

Startup Scout 19 Dec 2022

Green Bioactives grows medicines in plant cells

Though plants may hold the key to new, effective medicines, sourcing these compounds sustainably is difficult. Green Bioactives devises eco-friendly ways to produce plant-derived drugs via plant cell cultures. For decades, the pharmaceutical industry has designed synthetic small molecule drugs and manufactured them via chemical synthesis. While this approach provides an easy way to supply […]

December 19, 2022 - 4 minutesmins - By Jonathan Smith

malmomassan Malmö

News and Trends 19 Dec 2022

Watch: InfraLife supports Sweden’s life sciences industry

InfraLife (Infra Access for Life Science Sweden) is a Swedish initiative to maximize the benefits of Sweden’s large scale research infrastructures SciLifeLab, MAX IV and ESS. Funded by Swedish Research Council, InfraLife also partners with industrial organizations SwedenBIO & LIF and collaborates with SWElife, MedTech4Health and Swedish MedTech. The intent of the project is to […]

December 19, 2022 - 2 minutesmins - By Jim Cornall

malmomessan Malmö

News and Trends 19 Dec 2022

Watch: Pharm Assist at NLS Days

Pharm Assist is a consultancy company in Sweden offering regulatory affairs services for pharmaceutical and medical device companies. Founded in 1996, Pharm Assist employs more than 20 experts and has assisted more than 250 Nordic and international companies with their regulatory requirements. It acts as partner in product development, authoring and compilation of dossiers for […]

December 19, 2022 - 1 minutemin - By Jim Cornall

ADVERTISEMENT

Greece Greek flag

News and Trends 19 Dec 2022

Watch: Biotech in Greece

Greece was one of the countries exhibiting at Bio-Europe, held in Leipzig, Germany. Greece isn’t necessarily well known for biotech, but it has good infrastructure, is located at a crossroads between Europe and Africa and the Middle East, and has excellent universities. And its biotech industry is certainly growing. Enterprise Greece spearheaded the biotech presence […]

December 19, 2022 - 1 minutemin - By Jim Cornall

Leipzig Messe Germany

News and Trends 19 Dec 2022

Watch: Atriva Therapeutics at BIO-Europe

Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. […]

December 19, 2022 - 1 minutemin - By Jim Cornall

Leipzig Messe Bio-Europe

News and Trends 19 Dec 2022

Watch: Adrenomed tackling huge issue of sepsis

Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Its mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead […]

December 19, 2022 - 1 minutemin - By Jim Cornall

bladder cancer

News and Trends 19 Dec 2022

UroGen completes bladder cancer phase 3 trial enrollment

UroGen Pharma Ltd. says its phase 3 ENVISION study of investigational agent UGN-102 (mitomycin) for intravesical solution in development for the treatment of LG-IR-NMIBC is fully enrolled. The study targeted enrollment of 220 patients across 90 sites and, assuming positive findings, UroGen anticipates submitting a New Drug Application (NDA) for UGN-102 in 2024. “Completing enrollment […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

acute myeloid leukaemia leukemia AML

News and Trends 19 Dec 2022

Ordaōs and Yatiri Bio to tackle AML

Ordaōs has announced a joint development agreement to create new therapeutics for two novel targets in acute myeloid leukemia (AML) with Yatiri Bio. Ordaōs is a biotechnology company designing novel mini-proteins to help drug hunters deliver life-saving treatments, and Yatiri Bio is a biotechnology company that has developed a proprietary platform that links patient proteomic […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

M&A Mergers and acquisitions

News and Trends 19 Dec 2022

Prenetics acquires ACT Genomics

Prenetics Global Limited is acquiring a majority stake in ACT Genomics Holdings Company Limited, an Asia based genomics company specializing in precision oncology with operations in Hong Kong, Taiwan, Japan, Singapore, Thailand and in the U.K. “With the addition of ACT’s technologies, capabilities and team, Prenetics will be well-positioned to accelerate the utilization of genetic […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

ADVERTISEMENT